The U.S. FDA approved supplemental indications for Gilead Sciences’ Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi (sofosbuvir 400 mg) tablets.
FDA approval makes Xolair the first available biologic for children ages 6 and up with uncontrolled allergic asthma.
